Lactobacillus ( DrugBank: - )


5 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病7
46悪性関節リウマチ1
51全身性強皮症1
97潰瘍性大腸炎9
299嚢胞性線維症4

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05576818
(ClinicalTrials.gov)
June 30, 202210/10/2022Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's DiseaseClinical Study Evaluating the Efficacy and Safety of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's DiseaseParkinson DiseaseDrug: Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibersTanta UniversityNULLRecruiting45 Years65 YearsAll66Phase 3Egypt
2NCT04871464
(ClinicalTrials.gov)
November 11, 202129/4/2021Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's DiseaseRole and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical StudyParkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Movement Disorders;Neurodegenerative Diseases;Central Nervous System Diseases;Nervous System DiseasesDrug: Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules;Other: PlaceboBeijing Friendship HospitalNULLRecruiting40 Years85 YearsAll240Phase 4China
3NCT04722198
(ClinicalTrials.gov)
October 27, 202015/1/2021Effects of Lactobacillus Plantarum PS128 on Symptoms of Early-onset Parkinson's Disease: a Pilot StudyEffects of Lactobacillus Plantarum PS128 on Symptoms of Early-onset Parkinson's Disease: a Pilot StudyEarly Onset Parkinson DiseaseDietary Supplement: PS128Professor Lu Neurological ClinicNULLRecruiting20 Years80 YearsAll20N/ATaiwan
4NCT04722211
(ClinicalTrials.gov)
July 6, 202015/1/2021Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease.Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease.Parkinson DiseaseDietary Supplement: PS128;Dietary Supplement: placeboProfessor Lu Neurological ClinicNULLRecruiting45 Years80 YearsAll120N/ATaiwan
5NCT04389762
(ClinicalTrials.gov)
June 4, 201930/4/2020PS128 May Improve Off Duration on Parkinson's DiseaseLactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot StudyParkinson DiseaseDietary Supplement: daily ingestion of Lactobacillus plantarum PS128Professor Lu Neurological ClinicNULLCompleted40 Years80 YearsAll60N/ATaiwan
6NCT04293159
(ClinicalTrials.gov)
May 14, 201919/2/2020Effect of Probiotic on Constipation in Patients With Parkinson's DiseaseEffect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson's DiseaseParkinson Disease;ConstipationDietary Supplement: Lactobacillus casei DG (Enterolactis duo®)University of SalernoRoberto Erro;Maria Teresa Pellecchia;Antonella Santonicola;Carolina CiacciRecruiting18 Years75 YearsAll30N/AItaly
7NCT03566589
(ClinicalTrials.gov)
July 2, 201812/6/2018Effects of PS128 on Parkinsonian SymptomsEffects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot StudyParkinson DiseaseDietary Supplement: Lactobacillus plantarum PS128Professor Lu Neurological ClinicNULLCompleted40 Years80 YearsAll30N/ATaiwan

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00664820
(ClinicalTrials.gov)
March 200818/4/2008Effects of Probiotics on Rheumatoid Arthritis PatientsEffects of Probiotics on Rheumatoid Arthritis PatientsRheumatoid ArthritisDietary Supplement: Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14Lawson Health Research InstituteUniversity of Western Ontario, Canada;St. Joseph's Health Care LondonCompleted18 Years80 YearsAll50N/ACanada

51. 全身性強皮症


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01497743
(ClinicalTrials.gov)
February 201220/12/2011Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic SclerosisProbiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic SclerosisSclerodermaDrug: LactobacillusUniversity of MichiganNULLWithdrawn18 YearsN/ABoth0Phase 4United States

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05118919
(ClinicalTrials.gov)
February 9, 202226/10/2021A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative ColitisA Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative ColitisUlcerative ColitisBiological: BGP-014;Biological: PlaceboBioGaia Pharma ABNULLRecruiting18 YearsN/AAll50Phase 1/Phase 2Sweden
2EUCTR2019-004578-25-SE
(EUCTR)
09/07/202127/12/2019A clinical study in patients with mild to moderate ulcerative colitis to test the tolerability of Lactobacillus reuteri BGP-014A randomised placebo-controlled safety study of Lactobacillus reuteri BGP-014 in patients with active mild to moderate ulcerative colitis Mild to moderate ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Name: BGP-014 Capsules
Product Code: BGP-014
INN or Proposed INN: Lactobacillus reuteri
Other descriptive name: LACTOBACILLUS REUTERI
BioGaia Pharma ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 1;Phase 2Sweden
3ChiCTR2000033953
2020-07-012020-06-18Effect of the probiotic on symptoms in patients with ulcerative colitis (UC)Effect of the probiotic on symptoms in patients with ulcerative colitis (UC) Ulcerative colitisPlacebo group:Maltodextrin;experimental group 1:Lactobacillus plantarum CCFM8610;experimental group 2:Lactobacillus plantarum N13;experimental group 3:Lactobacillus casei CCFM1059;Jiangnan UniversityNULLPendingBothPlacebo group:20;experimental group 1:20;experimental group 2:20;experimental group 3:20;China
4NCT04102852
(ClinicalTrials.gov)
September 30, 201917/9/2019Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC PatientsThe Role of Lactobacillus Rhamnosus GG (ATCC 53103) in the Modulation of the Inflammatory Process in the Mucosa of Ulcerative Colitis (UC) Patients With Mild-moderate Clinical ActivityUlcerative Colitis Chronic Mild;Ulcerative Colitis Chronic ModerateDietary Supplement: Lactobacillus rhamnosus GG ATCC 53103San Giovanni Addolorata HospitalOnlus S. AndreaCompleted18 Years65 YearsAll76Phase 1/Phase 2Italy
5NCT03798210
(ClinicalTrials.gov)
January 1, 20177/1/2019Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative ColitisThe Effect of Lactobacillus Reuteri ATCC PTA 4659 in Patients With Ulcerative ColitisUlcerative Colitis FlareDietary Supplement: Lactobacillus reuteri;Dietary Supplement: PlaceboUppsala UniversityNULLRecruiting18 Years80 YearsAll40Phase 2Sweden
6NCT03136419
(ClinicalTrials.gov)
October 31, 20165/4/2017Microbiota and Immune microEnvironment in PouchitisMicrobiota and Immune microEnvironment in Pouchitis: Randomized Controlled Trial Oral Administration of Lactobacillus Casei DG After Ileostomy Closure in Ileal Pouch MucosaPouchitis;Ulcerative Colitis;Ileal PouchDietary Supplement: Lactobacillus casei DG;Dietary Supplement: PlaceboUniversity of PadovaNULLRecruiting18 Years100 YearsAll32N/AItaly
7NCT00895336
(ClinicalTrials.gov)
March 201127/4/2009Lactobacillus GG in Pediatric Ulcerative Colitis (UC)An Open Label Pilot Study of Lactobacillus GG in Pediatric Ulcerative ColitisUlcerative ColitisBiological: Lactobacillus GGChildren's Hospital Medical Center, CincinnatiNULLWithdrawn5 Years18 YearsAll0Phase 2United States
8NCT00268164
(ClinicalTrials.gov)
June 200421/12/2005Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative ColitisLactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative ColitisUlcerative ColitisDrug: lactobacilus acidophilus & bifidobacterium animalis/lactisHvidovre University HospitalChr Hansen A/STerminated18 YearsN/ABoth48Phase 2Denmark
9NCT00510978
(ClinicalTrials.gov)
January 20022/8/2007Probiotics in GastroIntestinal DisordersOne Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative ColitisUlcerative Colitis;Crohn's DiseaseBiological: Bifidobacterium infantis 35624;Biological: Lactobacillus salivarius UCC118;Biological: PlaceboUniversity College CorkEuropean CommissionActive, not recruitingN/A75 YearsBoth360Phase 2/Phase 3Ireland

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01837355
(ClinicalTrials.gov)
March 201310/4/2013Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic FibrosisModulation of Intestinal and Pulmonary Inflammation by Lactobacillus Rhamnosus Diet Supplementation in Pediatric Cystic Fibrosis (MoHuM-1)Pulmonary Inflammation;Cystic Fibrosis;MicrobiotaDietary Supplement: Lactobacillus rhamnosus;Dietary Supplement: PlaceboCantonal Hospital of St. GallenSwiss Federal Institute of Technology;University Hospital Inselspital, BerneUnknown status6 Years20 YearsAll68N/ASwitzerland
2NCT01956916
(ClinicalTrials.gov)
October 201023/9/2013Probiotics in Cystic FibrosisEffects of LGG Administration in Children With Cystic Fibrosis: A Randomized Controlled TrialCystic FibrosisDietary Supplement: Lactobacillus rhamnosus GG;Dietary Supplement: placeboFederico II UniversityNULLCompleted2 Years18 YearsBoth110Phase 3Italy
3NCT01961661
(ClinicalTrials.gov)
September 20099/10/2013Probiotics on Intestinal Inflammation in Cystic FibrosisEffect of Probiotics on Intestinal Inflammation and Microflora in Cystic Fibrosis: a Pilot StudyCystic FibrosisDietary Supplement: Lactobacillus rhamnosus GG;Dietary Supplement: placeboFederico II UniversityNULLCompleted2 Years18 YearsBoth22Phase 3Italy
4NCT01737983
(ClinicalTrials.gov)
May 200912/7/2012Effect of Lactobacillus Reuteri in Cystic FibrosisLactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.CYSTIC FIBROSISDietary Supplement: Lactobacillus reuteri;Dietary Supplement: placeboAzienda Policlinico Umberto INULLCompleted6 Years42 YearsBoth61Phase 4Italy